Serum Immunoglobulin (G) as a Marker of Diabetic Nephropathy

Not Applicable

• Conditions: Diabetic Nephropathies

• Registration Number: NCT03212755
• Lead Sponsor: Assiut University

Brief Summary

Diabetes mellitus is a chronic disease that affects 366 million people worldwide ( 6.4 % of the adult population ) and is expected to rise to 522 million by 2030 . Diabetic nephropathy occurs in approximately one - third of all people with diabetes and is the leading cause of renal failure in developed and developing countries Diabetic nephropathy is a severe complication occurring in diabetic patients and it is associated with an increased risk of all- cause mortality , cardiovascular disease and progression to end stage renal disease , requiring costly renal replacement therapy in the form of dialysis or transplantation

Detailed Description

Not available

Study Timeline

• Status Verified: 2017-07
• Study First Submitted: 2017-07-07
• Study First Submitted QC: 2017-07-07
• Last Update Submitted: 2017-07-07
• Study First Posted: 2017-07-11
• Last Update Posted: 2017-07-11
• Study Start: 2017-08
• Primary Completion: 2019-06
• Study Completion: 2019-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

• type 2 diabetic patients

Exclusion Criteria

• patients with diabetes type 1 ,
• pregnant and lactating females ,
• patients with any congenital disease , Infection , Smokers , alcoholics , and drug abusers .

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
The number of patients with high level of immunoglobulin in serum	24 hours